Skip to content
Elagolix
Oriahnn, Orilissa (elagolix) is a small molecule pharmaceutical. Elagolix was first approved as Orilissa on 2018-07-23. It is used to treat abdominal pain in the USA. The pharmaceutical is active against gonadotropin-releasing hormone receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Orilissa
Combinations
Oriahnn
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Elagolix sodium
Tradename
Company
Number
Date
Products
ORILISSAAbbVieN-210450 RX2018-07-23
2 products, RLD, RS
Elagolix sodium
+
Elagolix sodium
+
Estradiol
+
Norethindrone acetate
Tradename
Company
Number
Date
Products
ORIAHNN (COPACKAGED)AbbVieN-213388 RX2020-05-29
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
oriahnnNew Drug Application2020-05-01
orilissaNew Drug Application2021-02-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
abdominal painHP_0002027D015746R10.9
Agency Specific
FDA
EMA
Expiration
Code
ELAGOLIX SODIUM, ORILISSA, ABBVIE
2023-07-23NCE
ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE / ELAGOLIX SODIUM, ORIAHNN (COPACKAGED), ABBVIE
2023-07-23NCE
2023-05-29NP
Patent Expiration
Patent
Expires
Flag
FDA Information
Elagolix Sodium, Orilissa, Abbvie
115422392039-07-23DS, DP
105375722036-09-01U-2735
106823512036-09-01U-2850
113445512034-03-14U-3388, U-3389
70569272024-09-10DS, DP
71762112024-07-06U-2360
74199832024-07-06DS, DPU-2360
Elagolix Sodium,Estradiol,Norethindrone Acetate / Elagolix Sodium, Oriahnn (Copackaged), Abbvie
108816592034-03-14U-2842
110454702034-03-14U-2842
114593052028-11-07DPU-2842
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01C: Hypothalamic hormones
— H01CC: Anti-gonadotropin-releasing hormones
— H01CC03: Elagolix
HCPCS
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OnychomycosisD014009B35.1—134—8
TineaD014005EFO_0007510B35.4———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameELAGOLIX
INNelagolix
Description
Elagolix is an organooxygen compound and an organonitrogen compound. It is functionally related to a gamma-amino acid.
Classification
Small molecule
Drug classgonadotropin releasing hormone (GnRH) receptor antagonists (nonpeptide)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F
Identifiers
PDB7BR3
CAS-ID834153-87-6
RxCUI—
ChEMBL IDCHEMBL1208155
ChEBI ID—
PubChem CID11250647
DrugBankDB11979
UNII ID5B2546MB5Z (ChemIDplus, GSRS)
Target
Agency Approved
GNRHR
GNRHR
Organism
Homo sapiens
Gene name
GNRHR
Gene synonyms
GRHR
NCBI Gene ID
2798
Protein name
gonadotropin-releasing hormone receptor
Protein synonyms
gnRH receptor, gnRH-R, gonadotropin-releasing hormone (type 1) receptor 1, leutinizing hormone releasing horomone receptor, leutinizing-releasing hormone receptor, luliberin receptor, type I GnRH receptor
Uniprot ID
Q92644
Mouse ortholog
Gnrhr (14715)
gonadotropin-releasing hormone receptor (Q61611)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Oriahnn - AbbVie
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 309 documents
View more details
Safety
Black-box Warning
Black-box warning for: Oriahnn
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
982 adverse events reported
View more details